RxDoctor Payments DataLook up a doctor →

Deepak Kilari, MD

Hematology & Oncology · Milwaukee, WINPI 1164652947

Payments from drug & device makers

$4,669,745in general payments, 2019–2025

Across 954 payments — averaging $4894.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exelixis Inc.$1.2M
  • Novartis$704K
  • Merck$691K
  • Amgen$231K
  • Seagen Inc.$214K
  • Boehringer Ingelheim International GmbH$209K
  • plus $1.4M from 20 others
$13,054in research payments, 2019–2025

Across 14 payments — averaging $932.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$12K
  • Regeneron$2K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,669,745 in reported general payments places this provider in the 95th percentile of 248 hematology & oncology providers in Wisconsin.

See all hematology & oncology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$41,898
Medicare patients
128
Services billed
533

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →